Galmed Pharmaceuticals Ltd. – O (NASDAQ:GLMD):
Galmed Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 9th.
The company is now up by 0.12% since yesterday’s close of $8.20.
Galmed Pharmaceuticals Ltd., launched on July 31, 2013, is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH)..
Shares last traded at $8.20 a tad below $8.51, the 50 day moving average and quite a bit higher than the 200 day moving average of $6.88. The 50 day moving average was down by -3.61% whereas the 200 day average was up by +19.16%.
As of the latest earnings report the EPS was $-1.22 and is expected to be $-0.94 for the current year with 12,219,000 shares presently outstanding. Next quarter’s EPS is forecasted at $-0.25 and the next full year EPS is anticipated to be $-0.96.
Short traders are more bullish on the company recently if you evaluate the downtick in short interest. The stock realized a fall in short interest of -59.33% as of October 13, 2017 from the last reporting period. Short interest fell 34,300 over that period. Days to cover decreased from 1.0 to 1.0 and the percentage of shorted shares is 0.00% as of October 13.
A few investment analysts have released ratings on the company recently. Equity analyst Seaport Global initiated coverage setting a rating of “Buy”.